Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (60-70Gy Vs.>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital

Criteria

Inclusion Criteria:

• 18≤Age≤75 years

• Cytologically or histologically verified pancreatic adenocarcinoma or clinically diagnosed as pancreatic cancer by multidisciplinary consultation

• locally advanced pancreatic cancer (LAPC)

• SBRT was not preceded by any targeted antitumor therapy

• ECOG 0-1

• Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures

Exclusion Criteria:

• Patients who have previously received related treatment because of pancreatic adenocarcinoma, such as radiotherapy, chemotherapy or focal treatment

• Patients with severe liver or kidney dysfunction

• Patients with obstructive jaundice

• Patients with mass ascites

• Patients participated in other clinical trials for less than three months

• Patients with other malignancies, or acute or other severe infections, with ulcerative colitis, inflammatory bowel disease, ect

• Unsuitable to participate in this clinical trial judged by the investigator